HuMAB companies Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : HuMAB companies

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: idos who wrote (951)	10/27/2009 6:11:58 PM
From: nigel bates	Read Replies (1) of 1022

>>Glaxo filed a lawsuit Oct. 8<< LONDON, Oct 8 (Reuters) - GlaxoSmithKline (LSE: GSK.L - news) has challenged a biotech patent held by Roche (Virt-X: ROG.VX - news) 's Genentech (NYSE: DNA - news) unit in a bid to give a clear run to its experimental cancer and arthritis drug Arzerra, being developed with Genmab) . The British drugmaker said on Thursday it had filed a declaratory judgment action at the U.S. District Court for the Southern District of Florida arguing the 'Cabilly' patent was invalid, unenforceable and not infringed by Arzerra. Genmab, a Danish biotech company whose prospects hinge on the success of Arzerra, said the legal case was not expected to affect its financial guidelines for 2009. The patent has been in dispute before. In February, the U.S. Patent and Trademark Office confirmed that Genentech's patent was valid, in a reversal of an earlier decision. A year earlier, the patent office had rejected the validity of the Cabilly patent, prompting Genentech to appeal. The patent remained in effect during that reexamination process. (Reporting by Ben Hirschler; Editing by Hans Peters)

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next